AI Article Synopsis
- Cardiovascular issues in seronegative spondyloarthropathies, especially ankylosing spondylitis, are significant but not fully understood, with 10% of AS patients showing key symptoms, primarily in advanced cases.
- Up to 50% of AS patients may experience diastolic dysfunction and various echocardiographic abnormalities such as aortic and mitral insufficiencies, while heart conduction issues can affect 1% to 33%.
- Psoriatic arthritis increases cardiovascular mortality risk by 1.3 times compared to the general population, with complications like myocarditis and pericarditis being common, highlighting the need for comprehensive cardiovascular assessments in these patients.
Article Abstract
Cardiovascular manifestations of seronegative spondyloarthropathies represent an important clinical problem which has not been fully elucidated. Clinically significant cardiovascular symptoms are present in 10% of patients with ankylosing spondylitis (AS), usually in the case of long-standing disease. The following echocardiographic abnormalities have been reported in AS: ascending aortitis, aortic insufficiency (1-34%), mitral insufficiency (1-76%), mitral valve prolapse (5.7-10%), and diastolic dysfunction (20-50%). Abnormalities of the cardiac conduction system may develop in 1% to 33% of AS patients as a consequence of postinflammatory scarring of the myocardium. Cardiovascular diseases are the leading cause of death (36.2%) of patients with psoriatic arthritis (PsA). The risk of death in PsA is 1.3 times greater than in the general population. The following echocardiographic abnormalities can be seen in PsA: fibrinous pericarditis (18.2%), myocarditis (15.9%), and valvular disease (5.7%). Diastolic dysfunction in PsA correlates with the presence of articular lesions and duration of psoriasis. The importance of a thorough investigation of the cardiovascular system in patients with seronegative spondyloarthropathies is emphasized.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Two case reports of MDA5-type seronegative dermatomyositis.
SAGE Open Med Case Rep
December 2024
Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Dermatomyositis (DM) is an autoimmune idiopathic inflammatory myopathy with characteristic dermatologic manifestations. Myositis-specific autoantibodies (MSAs) delineate DM subtypes and their prognoses. Uncommonly, patients present with distinct clinical features of DM, including photosensitive dermatitis, heliotrope rash, Gottron's papules, and nailfold changes; however, their autoimmune serology is negative for expected MSAs.
View Article and Find Full Text PDFSuccessful rituximab treatment in a seronegative rheumatoid arthritis patient with concurrent cold agglutinin syndrome and immune thrombocytopenia.
Rheumatol Int
December 2024
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Cold agglutinin disease, a subtype of cold-type autoimmune hemolytic anemia, is referred to as cold agglutinin syndrome (CAS) when it develops secondary to other conditions. Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by the peripheral destruction of platelets. While both CAS and ITP can occur in patients with rheumatoid arthritis (RA), their concurrent manifestation in a single patient has not been reported, leaving the optimal treatment strategy for such a complex case unclear.
View Article and Find Full Text PDFAn update on autoantibodies in the idiopathic inflammatory myopathies.
Nat Rev Rheumatol
January 2025
Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, UK.
Myositis-specific autoantibodies (MSAs) have become pivotal biomarkers for idiopathic inflammatory myopathies and have revolutionized understanding of the heterogeneous disease spectrum that affects both adults and children. The discovery and characterization of MSAs have substantially enhanced patient stratification based on clinical phenotype, thereby facilitating more precise diagnosis and ultimately improving management strategies. Advances in immunoassay technologies in the past 20 years have further propelled the field forward, enabling the detection of a growing repertoire of autoantibodies with high specificity and sensitivity; however, evolving research over the past decade has revealed that even within antibody-defined subsets, considerable clinical diversity exists, suggesting a broader spectrum of disease manifestations than previously acknowledged.
View Article and Find Full Text PDFAd26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge.
NPJ Vaccines
November 2024
Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
Vaccination with Ad26.RSV.preF, an Adenoviral serotype 26 vector encoding RSV F protein stabilized in its prefusion conformation, has previously shown to be immunogenic and protective in RSV seropositive adults and immunogenic in seropositive infants.
View Article and Find Full Text PDFClinical presentation and treatment response in ACPA-negative rheumatoid arthritis.
Joint Bone Spine
November 2024
UMR 1227 Lymphocytes B, Auto-immunité et Immunothérapies, University Brest, Inserm, CHU de Brest, Brest, France.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and potential extra-articular manifestations. This review compares the presentation and treatment response between anti-citrullinated protein antibodies (ACPA)-positive and ACPA-negative RA patients. The incidence of seronegative RA (rheumatoid factor [RF]-negative and ACPA-negative) has increased in recent decades, emphasizing the need for new diagnostic biomarkers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!